 |
|
 |
Norman Wolmark,
MD
Chairman
Norman Wolmark, M.D. is Chairman
and Principal Investigator of the National Surgical
Adjuvant Breast and Bowel Project (NSABP) which
is primarily funded by the NCI and is based on the
campus of Allegheny General Hospital in Pittsburgh,
Pennsylvania. He is also Professor and Chairman
of Human Oncology, Drexel University School of Medicine,
and Chairman of the Department of Human Oncology,
Allegheny General Hospital, Pittsburgh, Pennsylvania.
Professor Wolmark gained his MD at McGill University,
Montreal, Canada and he subsequently completed his
residency at the University of Pittsburgh. Professor
Wolmark was then appointed to the position of Cancer
Expert at the Surgery Branch of the National Cancer
Institute, Bethesda, Maryland. Professor Wolmark
is a member of numerous professional societies,
including the American Society of Clinical Oncology
(ASCO), the American Association for Cancer Research
(AACR) and the American Surgical Association (ASA).
He is a reviewer for the Journal of Clinical Oncology
and the New England Journal of Medicine, and an
editorial board member of the Journal of Women’s
Cancer and Clinical Breast Cancer. He also serves
on numerous boards and as an advisor to oncology
programs, societies and institutes throughout the
United States and Europe. |
 |
D. Lawrence
Wickerham, MD
Associate Chairman
D. Lawrence Wickerham, MD has
been the Associate Chairman of the National Surgical
Adjuvant Breast and Bowel Project (NSABP) since
1995 and is an Associate Professor of Human Oncology
at the Pittsburgh Campus of the Drexel University
School of Medicine. Dr. Wickerham has worked for
the NSABP (an international cancer research group
federally funded by the National Cancer Institute)
in several capacities since 1981.
He received his bachelor’s degree from Washington
and Jefferson College in Washington, Pennsylvania,
and received his medical degree from the University
of Pittsburgh. He is also currently an Associate
Professor of Human Oncology at the Pittsburgh campus
of Drexel University School of Medicine. He has
published numerous articles in medical journals
on the topic of breast cancer, has lectured throughout
the world to medical audiences and to the general
public, and is the recipient of a 1998 Recognition
Award from the National Cancer Institute for outstanding
performance in breast cancer prevention. In May
2004 Dr. Wickerham was recognized by the National
Breast Cancer Awareness Month (NBCAM) for his outstanding
contributions to the effort to raise awareness about
breast health and breast cancer. In addition, Dr.
Wickerham was the first recipient of the 2004 Adams
County Breast Cancer Coalition first annual breast
cancer research award.
|
 |
Michael O’Connell,
MD
Associate Chairman
Michael O'Connell, MD, serves
as Associate Chairman of the National Surgical Adjuvant
Breast and Bowel Project. An internationally recognized
specialist in the treatment of gastrointestinal
tract cancers, Dr. O'Connell is a prolific researcher
who has authored or co-authored more than 200 peer
reviewed journal articles, 150 scientific abstracts
and 25 textbook chapters in his field. His work
has been widely published by leading scientific
journals, including the New England Journal of Medicine,
the Journal of the American Medical Association,
Cancer, and the Journal of Clinical Oncology.
Dr. O'Connell has helped direct numerous studies
that have resulted in better treatment protocols
for cancer of the colon and rectum. He is currently
a leader of a national study to determine the efficacy
of combining a new anti-angiogenesis therapy, called
bevacizumab (Avastin), with standard chemotherapy
in patients who have already had surgery for stage
II or stage III colon cancer.
A graduate of the University of Minnesota Medical
School, Dr. O'Connell completed post-graduate training
with an internal medicine residency at the University
of Minnesota Hospitals and a fellowship in oncology
as a clinical associate at NCI's Baltimore Cancer
Research Center.
Dr. O'Connell is a member of the American Society
of Clinical Oncology and the American Association
for Cancer Research. He is also on the Board of
Directors for the Coalition of National Cancer Cooperative
Groups and serves as a member of the NCI steering
committee for gastrointestinal cancer cooperative
group clinical trials. In 1996, he was among a select
group of cancer specialists invited to the White
House for President Clinton's announcement of major
changes in FDA policy for approval of oncology drugs
and was selected to participate in the National
Dialogue on Cancer chaired by President and Mrs.
George H. Bush and the 2001 World Summit Against
Cancer in Paris, France. |
 |
Joan Beyer
Goldberg, MPH
Chief Executive Officer
Joan Beyer Goldberg, MPH, has
spent more than 30 years in healthcare management.
As a member of senior management for two large university
affiliated teaching hospitals with major programs
in medical research, Mrs. Goldberg has brought extensive
management and business experience to the NSABP
Foundation, Inc. Since becoming CEO in 1998, Mrs.
Goldberg has managed the growing organization. In
1999, the Foundation became the recipient of the
NCI grant which has been the core support for the
NSABP since 1958. Since 1998 the laboratory and
clinical activities have experienced significant
expansion and in 2005 the 100,000th patient was
accrued to an NSABP clinical study. A graduate of
the University of Pittsburgh, Graduate School of
Public Health, Mrs. Goldberg has received numerous
awards in recognition of her leadership in the field.
|
 |
Soonmyung
Paik, MD
Director, Pathology
Soonmyung Paik, M.D. is a pathologist
with training in molecular biology. He graduated
from the College of Medicine, Yonsei University,
Seoul, Korea in 1981 and received his residency
training in the United States. After completing
his residency, he joined Dr. Marc Lippman’s group
at the National Cancer Institute as a post-doctoral
fellow and was a faculty member at the Lombardi
Cancer Center, Georgetown University. In 1996 he
was appointed director of the Division of Pathology
for the NSABP. His main research interest is in
developing predictive markers to improve and target
the treatment of breast cancer. His division maintains
one of the largest annotated breast cancer tissue
banks in the world. |
 |
Charles E.
Geyer, Jr., MD
Director, Medical Affairs
Co-Director, NSABP Foundation
Research Program
Charles E. Geyer, Jr., M.D., FACP, is a board certified
medical oncologist with expertise in the study and
treatment of breast cancer. Currently, he is Director
of Medical Affairs for the National Surgical Adjuvant
Breast and Bowel Project (NSABP), Co-Director of
the NSABP Foundation Research Program (FRP), and
Director of Breast Medical Oncology, Allegheny General
Hospital. As Director of Medical Affairs he is responsible
for medical oversight of the Phase III clinical
trial programs in breast and colorectal cancer.
As Co-Director of the FRP, he is responsible for
the design and conduct of Phase II clinical trials
in breast cancer. He served as the protocol officer
for a recent study that proved that the drug Herceptin™
(trastuzumab) dramatically improved the risk of
recurrent cancer among women treated for HER2 positive
early stage breast cancer. His current academic
appointment is Associate Professor of Medicine at
Drexel University College of Medicine. A graduate
of Texas Tech University School of Medicine, Dr.
Geyer completed his medical residency, chief medical
residency and Medical Oncology Fellowship at the
Baylor College of Medicine Affiliated Hospitals
in Houston, Texas. |
 |
Carmen Allegra,
MD
Co-Director, Foundation Research Program
Carmen Allegra, M.D., is a board certified medical
oncologist with expertise in the study and treatment
of colorectal cancer. Currently, he is Co-Director
of the Foundation Research Program for the National
Surgical Adjuvant Breast and Bowel Project (NSABP)
and Medical Director for the Network for Medical
Communication and Research. His FRP responsibilities
include the development and oversight of clinical
trials in colorectal cancer. He serves as the Principal
Investigator for the ongoing investigation of the
role of bevacizumab, an anti-VEGF antibody, in the
treatment of patients with localized colon cancer.
Prior to joining the FRP, Dr. Allegra developed
an international reputation through his extensive
contributions to the medical literature during his
20 years as an investigator and Medicine Branch
Chief at the National Cancer Institute. During this
time he investigated various prognostic and predictive
markers for patients with cancer and developed new
therapeutic strategies for patients with both cancer
and AIDS. A graduate of the University of Pennsylvania
School of Medicine and medical residency program,
Dr. Allegra completed his Medical Oncology Fellowship
at the National Cancer Institute in Bethesda, Maryland.
|
 |
Thomas Julian,
MD
Associate Director, Medical Affairs
Thomas Julian, MD is
an accomplished breast cancer surgeon, researcher,
and educator, currently serving as Associate Director
of the Allegheny Breast Center, Staff Surgeon in
the Division of Surgical Oncology at Allegheny General
Hospital, and Associate Professor, Human Oncology
at Drexel University College of Medicine. He has
been a principal investigator for numerous breast
cancer pre-and post launch clinical trials studying
topics such as primary systemic combination drug
therapy in postmenopausal hormone-receptor positive
breast cancer patients, the GeneSearch™ breast
lymph node assay for intraoperative molecular testing,
digital mammography imaging, and MRI evaluation
of the contralateral breast in recently diagnosed
female breast cancer patients, among others. Together
with colleagues Yoed Rabin and Norman Wolmark, Dr.
Julian was awarded two US patents for developing
new methods and equipment for use in cryosurgery.
From 2002-present, he is the Protocol Officer for
3 breast cancer trials conducted by the National
Surgical Adjuvant Breast and Bowel Project (NASBP),
for which he serves as Associate Director of Medical
Oversight. Dr. Julian’s research and expertise
have been widely published, appearing in over 120
articles, reviews, book chapters, audio-visual displays,
abstracts, and scientific exhibits. He completed
his undergraduate in chemistry at University of
Pittsburgh, and obtained his MD degree from the
University of Pittsburgh School of Medicine. |
 |
David S.
Parda, MD, FACP
Associate Director, Medical Affairs
David S. Parda, MD, FACP, is
Chairman of the Department of Radiation Oncology,
Allegheny General Hospital, and the West Penn Allegheny
Health System Radiation Oncology Network, and serves
as Associate Director for the National Surgical
Adjuvant Breast and Bowel Project. He has developed
8 primary programs in radiation oncology (clinical
program, technical program, clinical research program,
IT program, residency training/education program,
industry collaboration program, translational/correlative
science program, community outreach program) to
integrate a network of 9 radiation oncology clinics
in Western Pennsylvania and Eastern Ohio with advanced
technologies and data collection processes to optimize
standard and advancing patient care. This has resulted
in one of the nation’s most comprehensive
radiation oncology centers at AGH and throughout
WPAHS Radiation Oncology Network with clinical and
technical expertise consistent with the most sophisticated
academic radiation oncology practices.
As
a contributing investigator in two of the nation’s
preeminent cancer study groups, the National Surgical
Adjuvant Breast and Bowel Project (NSABP) and
the Radiation Therapy Oncology Group (RTOG), Dr.
Parda has played a key role in research that has
greatly improved the treatment of cancer patients.
He is currently the radiation
protocol officer for NSABP B-39, a study that
will determine whether limiting radiation therapy
to only the tumor site following lumpectomy, a
procedure known as partial breast irradiation,
is as effective as irradiating the whole breast
in the local management of early stage breast
cancer.
Dr. Parda received his Bachelor
of Arts degree with honors in molecular biology
and psychology from Vanderbilt University and
his medical degree from the University of South
Florida College of Medicine. He completed a residency
in internal medicine at the Cleveland Clinic Foundation
and a residency in radiation oncology at Georgetown
University and is board certified in both internal
medicine and radiation oncology.
Through special training
at the National Cancer Institute (NCI) Laboratory
of Cellular and Molecular Biology, Georgetown
University's Lombardi Cancer Center and Memorial
Sloan-Kettering Cancer Center, Dr. Parda has acquired
noted expertise in the multidisciplinary treatment
of cancer. His clinical and research interests
include breast cancer; colorectal cancer; head
and neck cancer, including eye and orbit; Intensity-Modulated
Radiation Therapy (IMRT); Image-Guided Radiation
Therapy (IGRT); Adaptive Radiation Therapy (ART);
functional and 4D data incorporation into radiation
treatment planning; oncology information systems/electronic
medical record integration processes; clinical
trials and correlative/translational science research;
medical education; quality assurance/peer review;
and brachytherapy. Dr. Parda has held appointments
as an assistant professor of radiation oncology
at Georgetown University, MCP Hahnemann University
School of Medicine and the University of Pittsburgh
School of Medicine and is currently an Associate
Professor of Radiation Oncology at Drexel University
College of Medicine. He is a member of the American
College of Radiology, American Medical Association,
American Society for Therapeutic Radiology and
Oncology and the Society of Chairs of Academic
Radiation Oncology Programs. He is the Radiation
Oncology Protocol Officer for the National Surgical
Adjuvant Breast and Bowel Project (NSABP), Radiation
Therapy Oncology Group (RTOG) and NCI-sponsored
Partial Breast Irradiation Clinical Trial, a member
of the NCI Central Institutional Review Board,
an examiner for the American Board of Radiology
Radiation Oncology Resident Oral Board Examination,
a board member of the Pennsylvania Society of
Oncology and Hematology, a Director-At-Large on
the Pennsylvania Board of Directors of the American
Cancer Society, a peer review consultant for the
American Medical Foundation for Peer Review and
Education, and is the Radiation Oncology Residency
Program Director at AGH.
|
 |
Mark Roh,
MD
Associate Director, Medical Affairs
Mark Roh, M.D., serves
as Associate Director, for the National Surgical
Adjuvant Breast and Bowel Project and was appointed
chairman of the Department of Surgery at Allegheny
General Hospital in July 1998. He was appointed
chairman of the Council of Graduate Medical Education
at AGH in 2002. Dr. Roh earned his medical degree
in 1979 at The Ohio State University College of
Medicine and a bachelor of arts at Ohio Wesleyan
University in 1976. He obtained his surgical training
at the University of Pittsburgh Medical Center.
He completed his surgical oncology training in
1987 at Memorial Sloan-Kettering Cancer Center
in New York City. From 1987 to 1997, he served
as chief of Liver Tumor Surgery at the M.D. Anderson
Cancer Center in Houston. Since coming to Allegheny
General in 1997, Dr. Roh has served as the director
of the Division of Surgical Oncology at Allegheny
General Hospital since 1997.
He has been recognized by the
Best Surgeons in the United States, Best Doctors
in America and the Who’s Who in America
beginning in 1992 to the present. Other honors
include teaching awards, the Faculty Excellence
Award at M.D. Anderson and the Resident Research
Award from the Association for Academic Surgery
and the Pittsburgh Academy of Medicine. Roh has
served as an editor since 1994 of the Annals of
Surgical Oncology and recently was appointed as
the Executive Editor.
|
 |
Saima Sharif,
MD
Assistant Director, Medical Affairs
Saima Sharif, MD, MS, is a
board certified medical oncologist with a special
interest in the treatment of gastrointestinal cancers.
She is currently the Assistant Director of Medical
Affairs for the National Surgical Adjuvant Breast
and Bowel Project (NSABP). Dr Sharif is involved
in developing concepts for future phase III NSABP
colorectal protocols and phase II protocols for
the NSABP’s Foundation Research Program. She serves
as the protocol officer for adjuvant and metastatic
colon trials; two current trials she is overseeing
involve the use of standard chemotherapy combined
with an anti-angiogenesis agent in the adjuvant
setting and also in patients with metastatic colon
cancer whose primary tumor is intact and asymptomatic
but the disease is not amenable to surgery.
Dr. Sharif received her medical degree from Dow
Medical College, University of Karachi, Pakistan.
She completed her internal medical residency at
Tufts University and her medical oncology fellowship
at the University of Pittsburgh. During her fellowship,
she earned a Master of Science degree in clinical
research, specializing in clinical epidemiology,
under an NIH training grant. Dr Sharif remains active
at the University of Pittsburgh, working on investigations
of gene-environment interactions that may increase
susceptibility for pancreatic cancer, the subject
of her thesis. |
|
 |
| |
|
|
